4
Changes in Ownership
Nurix Therapeutics, Inc. Filed Acc 0001209191-22-000730
Chief Scientific Officer sold 1,828 shares at $28.96 ($52,939)
- Chief Scientific Officer acquired 1,828 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Hansen Gwenn · Chief Scientific Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-01-03 | Exercise or conversion : show line 1 in the form | +400 | $7.26 | $2,904 | 14,597 | D |
| 2022-01-03 | Exercise or conversion : show line 2 in the form | +1,428 | $9.57 | $13,666 | 16,025 | D |
| 2022-01-03 | Sale : show line 3 in the form | −1,828 | $28.96 | $52,939 | 14,197 | D |
| Open-market sales · 1,828 sh · avg $28.96 · $52,939 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-01-03 | Exercise or conversion : show line 4 in the form Employee Stock Option (right to buy) | −400 | 67,466 | D |
| 2022-01-03 | Exercise or conversion : show line 5 in the form Employee Stock Option (right to buy) | −1,428 | 81,905 | D |
Loading xslF345X03/doc4.xml…